文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤泌尿男性生殖肿瘤

立体定向体部放疗联合检查点抑制剂治疗晚期实体瘤:CHEERS 2期随机临床试验

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项在5家比利时医院开展的开放标签、多中心、随机2期试验纳入99例晚期实体瘤患者,随机接受抗PD-1/PD-L1单药(对照组52例)或联合立体定向体部放疗3×8 Gy(试验组47例)。可分析96例中,中位无进展生存期对照组2.8个月 vs 试验组4.4个月(HR 0.95,95%CI 0.58-1.53,P=0.82),中位总生存期11.0 vs 14.3个月(HR 0.82,95%CI 0.48-1.41,P=0.47),客观缓解率22% vs 27%(P=0.56)。

要点

  • 在免疫检查点抑制剂基础上加用亚消融立体定向放疗未改善无进展生存期或总生存期。
  • 试验组与对照组的安全性相似,未发生5级不良事件。
  • 受照射病灶局部控制率为75%。

核心结论

  • 在免疫检查点抑制剂单药基础上对有限数目转移灶加用亚消融立体定向放疗虽然安全,但未能改善无进展生存期或总生存期。

研究设计与样本

  • 开放标签、多中心、随机2期试验,在5家比利时医院开展,2018年3月至2020年10月入组。
  • 纳入18岁及以上局部晚期或转移性黑色素瘤、肾细胞癌、尿路上皮癌、头颈鳞状细胞癌或非小细胞肺癌患者。
  • 共99例随机分配至对照组(n=52)或试验组(n=47),3例撤回知情同意未纳入分析。
  • 随机按肿瘤组织学类型和疾病负荷(≤3个或>3个病灶)分层。

主要发现

  • 可分析96例(平均年龄66岁;76例[79%]女性),72例(75%)有超过3个肿瘤病灶,65例(68%)入组时已接受至少1线既往系统治疗。
  • 中位随访12.5个月(范围0.7-46.2),中位无进展生存期对照组2.8个月 vs 试验组4.4个月(HR 0.95,95%CI 0.58-1.53,P=0.82)。
  • 中位总生存期对照组11.0个月 vs 试验组14.3个月(HR 0.82,95%CI 0.48-1.41,P=0.47)。
  • 客观缓解率对照组22% vs 试验组27%,差异无统计学意义(P=0.56);受照射患者局部控制率为75%。
  • 任何级别急性治疗相关毒性对照组79% vs 试验组78%,3级及以上对照组18% vs 试验组18%;未发生5级不良事件。

关键数值与推荐

  • 试验组在第二或第三周期免疫检查点抑制剂前接受立体定向体部放疗3×8 Gy,最多照射3个病灶,具体取决于给药频率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs. OBJECTIVE: To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, or non-small cell lung carcinoma were eligible. A total of 99 patients were randomly assigned to either the control arm (n = 52) or the experimental arm (n = 47). Of those, 3 patients (1 in the control arm vs 2 in the experimental arm) withdrew consent and thus were not included in the analysis. Data analyses were performed between April 2022 and March 2023. INTERVENTIONS: Patients were randomized (1:1) to receive anti-PD-1/PD-1 ligand 1 ICIs alone as per standard of care (control arm) or combined with stereotactic body radiotherapy 3 × 8 gray to a maximum of 3 lesions prior to the second or third ICI cycle, depending on the frequency of administration (experimental arm). Randomization was stratified according to tumor histologic findings and disease burden (3 and fewer or more than 3 cancer lesions). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) as per immune Response Evaluation Criteria in Solid Tumors. Key secondary end points included overall survival (OS), objective response rate, local control rate, and toxic effects. Efficacy was assessed in the intention-to-treat population, while safety was evaluated in the as-treated population. RESULTS: Among 96 patients included in the analysis (mean age, 66 years; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previous line of systemic treatment at time of inclusion. Seven patients allocated to the experimental arm did not complete the study-prescribed radiotherapy course due to early disease progression (n = 5) or intercurrent illness (n = 2). With a median (range) follow-up of 12.5 (0.7-46.2) months, median PFS was 2.8 months in the control arm compared with 4.4 months in the experimental arm (hazard ratio, 0.95; 95% CI, 0.58-1.53; P = .82). Between the control and experimental arms, no improvement in median OS was observed (11.0 vs 14.3 months; hazard ratio, 0.82; 95% CI, 0.48-1.41; P = .47), and objective response rate was not statistically significantly different (22% vs 27%; P = .56), despite a local control rate of 75% in irradiated patients. Acute treatment-related toxic effects of any grade and grade 3 or higher occurred in 79% and 18% of patients in the control arm vs 78% and 18% in the experimental arm, respectively. No grade 5 adverse events occurred. CONCLUSIONS AND RELEVANCE: This phase 2 randomized clinical trial demonstrated that while safe, adding subablative stereotactic radiotherapy of a limited number of metastatic lesions to ICI monotherapy failed to show improvement in PFS or OS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03511391.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Spaas M, Sundahl N, Kruse V, et al. Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37410476. doi:10.1001/jamaoncol.2023.2132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。